A new class of diamine-based human histamine H3 receptor antagonists: 4-(Aminoalkoxy)benzylamines

Journal of Medicinal Chemistry

Volumn 46, Issue 18, 2003, Pages 3938-3944

  Apodaca, Richard ^a   Dvorak, Curt A ^a   Xiao, Wei ^a   Barbier, Ann J ^a   Boggs, Jamin D ^a   Wilson, Sandy J ^a   Lovenberg, Timothy W ^a   Carruthers, Nicholas I ^a  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 [4 (3 PIPERIDIN 1 YLPROPOXY)BENZYL]PIPERIDINE; BENZYLAMINE DERIVATIVE; HISTAMINE H3 RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; DRUG ACTIVITY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IN VITRO STUDY; NONHUMAN; STRUCTURE ANALYSIS;

ANIMALS; BENZYLAMINES; CACO-2 CELLS; CELL LINE; CEREBRAL CORTEX; CYCLIC AMP; HISTAMINE ANTAGONISTS; HUMANS; PERMEABILITY; PIPERIDINES; RATS; RECEPTORS, HISTAMINE H3; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0041418310     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm030185v     Document Type: Article

References (47)

1. Hough, L. B. Genomics Meets Histamine Receptors: New Subtypes, New Receptors. Mol. Pharmacol. 2001, 59, 415-419.
2. 3 Receptor and Its Ligands. Prog. Med. Chem. 2001, 38, 279-308.
3. 3 Receptor: A Target for New Drugs; Leurs, R.; Timmerman, H., Eds.; Elsevier Science B.V.: Amsterdam, 1998; pp 13-26.
4. 3 receptor agonists and antagonists. Trends Pharmacol. Sci. 1998, 19, 177-183.
5. 3 receptor. In Progress in Drug Research; Jucker, E., Ed.; Birkenhäuser Verlag: Basel, Switzerland, 1995; Vol. 45, pp 107-165.
6. 3 Receptor Pharmacotherapy Targets in Gastrointestinal Disorders. In Drug Development: Molecular Targets for GI Diseases; Gaginella, T. S., Guglietta, A., Eds.; Humana Press Inc., Totowa, NJ, 2000; pp 239-267.
7. 3-Receptors: A New Frontier in Myocardial Ischemia. J. Pharmacol. Exp. Ther. 2000, 292, 825-830.
8. (a) Halpern, M. T. GT-2331 Gliatech Inc Curr. Opin. Cent. Peripher. Nerv. Syst. Invest. Drugs 1999, 1, 524-527.
9. 3 Receptor Agonist Prodrug. J. Pharmacol. Exp. Ther. 1997, 281, 1085-1094.
10. 3-Receptors Control Histamine Release in Human Brain. J. Neurochem. 1988, 51, 105-108.
11. 3 receptors. Eur. J. Pharmacol. 2002, 453, 33-41.
12. 3 Receptors. Bioorg. Med. Chem. Lett. 2001, 11, 951-954.
13. 3 receptors: role of two amino acids in the third transmembrane domain. Br. J. Pharmacol. 2000, 131, 1247-1250.
14. 3 Receptor Reveals Distinct Species Pharmacological Profiles. J. Pharmacol. Exp. Ther. 2000, 293, 771-778.
15. α-methylhistamine binding differ from that of rodents. Eur. J. Pharmacol. 1999, 377, 233-239.
16. 3 Receptor. Mol. Pharmacol. 1999, 55, 1101-1107.
17. 3 receptor subtypes and splice variants is an area of active investigation. For a discussion, see ref 8a and references therein.
18. 3-receptor antagonists. Drugs Future 1996, 21, 507-520.
19. 1 blocking activities. Farmaco 1999, 54, 684-694.
20. 3 Antagonists. Arch. Pharm. (Weinheim, Ger.) 1999, 332, 389-398.
21. 3 Receptor Antagonists. J. Med. Chem. 2000, 43, 2362-2370.
22. 3 Receptor Antagonists. Bioorg. Med. Chem. Lett. 2002, 12, 3309-3312.
23. 3 Receptor Antagonists. Bioorg. Med. Chem. Lett. 2003, 13, 1767-1770.
24. 3 Receptor Ligands with Combined Inhibitory Histamine N-Methyltransferase Activity. J. Med. Chem. 2002, 45, 1128-1141.
25. 3 Receptor Ligands. Part 1. Bioorg. Med. Chem. Lett. 2002, 12, 2031-2034.
26. 3 Receptor Ligands. Part 2: Binding Preference for D-Amino Acids Motifs. Bioorg. Med. Chem. Lett. 2002, 12, 2035-2037.
27. (c) Vasudevan, A.; Conner, S. E.; Gentles, R. G.; Faghih, R.; Liu, H.; Dwight, W.; Ireland, L.; Kang, C. H.; Esbenshade, T. A.; Bennani, Y.; Hancock, A. A. Bioorg. Med. Chem. Lett. 2002, 12, 3055-3058.
28. (d) Faghih, R.; Dwight, W.; Vasudevan, A.; Dinges, J.; Conner, S. E.; Esbenshade, T. A.; Bennani, Y. L.; Hancock, A. A. Bioorg. Med. Chem. Lett. 2002, 12, 3077-3079.
29. 3 receptors. Psychopharmacology 1994, 116, 464-468.
30. 3-receptors in rat brain. Eur. J. Pharmacol. 1988, 157, 31-35.
31. Pompni, S. A.; Gullo, V. P.; Horan, A. C.; Patel, M. G.; Coval, S. Method for Treating Airway Congestion. U.S. Patent 5,352,707, 1994.
32. 3-receptor antagonists. Eur. J. Pharm. Sci. 2001, 13, 249-259.
33. 3-Receptor Antagonists. Arch. Pharm. (Weinheim, Ger.) 1998, 331, 395-404.
34. 3 Inhibitors. Bioorg. Med. Chem. Lett. 2002, 12, 2643.
35. 3 Receptor Antagonists: 1-(4-(Phenoxymethyl)-benzyl)piperidines and Related Compounds. J. Med. Chem. 2003, 46, 1523-1530.
36. Kolb, H. C.; Finn, M. G.; Sharpless, K. B. Click Chemistry: Diverse Chemical Function from a Few Good Reactions. Angew. Chem., Int. Ed. 2001, 40, 2004-2021.
37. Abdel-Magid, A. F.; Carson, K. G.; Harris, B.D.; Maryanoff, C. A.; Shah, R. D. Reductive Amination of Aldehydes and Ketones with Sodium Triacetoxyborohydride. Studies on Direct and Indirect Reductive Amination Procedures. J. Org. Chem. 1996, 61, 3849-3862.
38. Walsh, D. A.; Franzyshen, S. K.; Yanni, J. M. Synthesis and Antiallergy Activity of 4-(Diarylhydroxymethyl)-1-[3-(aryloxy)-propyl]piperidines and Structurally Related Compounds. J. Med. Chem. 1989, 32, 105-118.
39. (a) Tunoori, A. R.; Dutta, D.; Georg, G. I. Polymer-Bound Triphenylphosphine as Traceless Reagent for Mitsunobu Reactions in Combinatorial Chemistry: Synthesis of Aryl Ethers from Phenols and Alcohols. Tetrahedron Lett. 1998, 39, 8751-8754.
40. (b) Kiankarimi, M.; Lowe, R.; McCarthy, J. R.; Whitten, J. P. Diphenyl 2-Pyridylphosphine and Di-tert-butyl Azodicarboxylate: Convenient Reagents for the Mitsunobu Reaction. Tetrahedron Lett. 1999, 40, 4497-4500.
41. (a) Uveges, A. J.; Kowal, D.; Zhang, Y.; Spangler, T. B.; Dunlop, J.; Semus, S.; Jones, P. G. The Role of Transmembrane Helix 5 in Agonist Binding to the Human H3 Receptor. J. Pharmacol. Exp. Ther. 2002, 301, 451-458.
42. 3 Receptor Antagonists, Using the Newly Developed Molecular Modeling Program SLATE. J. Med. Chem. 2001, 44, 1666-1674.
43. 3 Receptor Explaining Agonistic and Antagonistic Activity Simultaneously. Arch. Pharm. (Weinheim, Ger.) 2000, 333, 254-260.
44. +-ATPase Inhibitory Activity. J. Med. Chem. 1988, 31, 1778-1785.
45. Mariani, E.; Bargagna, A.; Longobardi, M.; Schenone, P.; Vitagliano, S.; Cenicola, M. L.; Losasso, C.; Russo, S.; Marmo, E. 5-[4-(ω-Dialkylaminoalkoxy)phenmethylene]-1,3,3-trimethyl-2-oxabicyclo[2. 2.2]octan-6-ones with Platelet Antiaggregating and Other Activities. Farmaco 1991, 46, 657-668.
46. Kabalka, G. W.; Wu, Z.; Ju, Y. Alkylation of aromatic aldehydes with alkylboron chloride derivatives. Tetrahedron 2001, 57, 1663-1670.
47. Rejzek, M.; Wimmer, Z.; Šaman, D.; Ricánková, M. 113. Synthesis and Structure-Activity Relationships of Juvenoids Derived from 2-(4-Hydroxybenzyl)cycloalkan-1-ones. Helv. Chim. Acta 1994, 77, 1241-1255.